Vertex Pharmaceuticals (VRTX) Interest & Investment Income (2009 - 2026)

Vertex Pharmaceuticals' Interest & Investment Income history runs 18 years deep, the most recent figure standing at $114.8 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 2.63% year-over-year to $114.8 million; the TTM figure through Mar 2026 stood at $484.8 million (down 9.35% YoY), while the FY2025 annual figure was $490.9 million, down 17.92% from the prior year.
• Interest & Investment Income was $114.8 million for Q1 2026 at Vertex Pharmaceuticals, down from $121.9 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $181.2 million in Q1 2024 to a low of $1.6 million in Q1 2022.
• Historically, Interest & Investment Income has averaged $115.3 million across 5 years, with a median of $122.6 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Interest & Investment Income surged 7562.5% in 2023, then sank 34.93% in 2025.
• A 5-year view of Interest & Investment Income shows it stood at $86.0 million in 2022, then surged by 108.72% to $179.5 million in 2023, then declined by 28.58% to $128.2 million in 2024, then fell by 4.91% to $121.9 million in 2025, then decreased by 5.82% to $114.8 million in 2026.
• The last three Interest & Investment Income figures came in at $114.8 million (Q1 2026), $121.9 million (Q4 2025), and $125.7 million (Q3 2025), per Business Quant data.